Document Detail


The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: A systematic review and qualitative analysis of the literature.
MedLine Citation:
PMID:  21992675     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract The increase of fludarabine-resistant chronic lymphocytic leukemia (CLL) presents a new treatment challenge. The aim of this review is to evaluate the efficacy and safety of rituximab for patients with fludarabine-refractory CLL. Medline, Embase, the Cochrane Library, and selected conference proceedings were searched. Seventeen relevant publications reporting stratified data were identified. Treatments included: rituximab in combination with etanercept, alemtuzumab, bendamustine, or methylprednisolone alone, with fludarabine and cyclophosphamide (FCR), with oxaliplatin as well as fludarabine and cytarabine, with cyclophosphamide as well as fludarabine and alemtuzumab (CFAR), and cytarabine, cisplatinum and dexamethasone (DHAP). One study evaluated rituximab with granulocyte macrophage colony-stimulating factor in combination with alternating cyclophosphamide, liposomal daunorubicin, vincristine, dexamethasone, and methotrexate plus Ara-C. One study evaluated rituximab as monotherapy. Of the nine studies considering overall response, eight reported rates above 50% (four reported rates above 75%). Median overall survival was 37 months for FCR, 11 months for CFAR, 20 months for rituximab with methylprednisolone, 30 months for rituximab with alemtuzumab, and 44 months for an FCR/CFAR mixed treatment. The identified studies indicate that regimens containing rituximab may be highly efficacious in the fludarabine-refractory CLL setting. Nevertheless, further research is needed to facilitate the choice of treatment for the clinician.
Authors:
Stéphane Lepretre; Uli Jäger; Ann Janssens; Veronique Leblond; Eugene Nikitin; Tadeusz Robak; Clemens-Martin Wendtner
Related Documents :
21802685 - Etoposide, cisplatin-etoposide, methotrexate, actinomycin-d as primary treatment for ma...
25267745 - Utility of routine post-therapy surveillance imaging in diffuse large b-cell lymphoma.
8260235 - Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma.
7900705 - A phase ii study of 5-fluorouracil plus high-dose folinic acid in the treatment of recu...
22678155 - Sentinel lymph node biopsy of the internal mammary chain in breast cancer.
22567145 - Riboflavin ameliorates cisplatin induced toxicities under photoillumination.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-10-13
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  -     ISSN:  1029-2403     ISO Abbreviation:  -     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Compulsory community treatment and patients' perception of recovery in schizophrenia.
Next Document:  Clinical Implications of the Molecular Subtypes of Diffuse Large B-Cell Lymphoma.